An interventional study of Blood flow Restriction therapy and ESWT in Supraspinatus Tendinitis, sponsored by Sehat Medical Complex. Completed at 1 site in Pakistan. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Sehat Medical Complex · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Tendinopathy with a site in Pakistan — 1 open to participants now, 3 under way, none of them phase 3. Tendinopathy · Pakistan.
Among the 12 studies in Tendinopathy with a site in Pakistan, this one is the 2nd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 8th registered.
399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.
Browse Tendinopathy studies →1 of the 12 studies in Tendinopathy with a site in Pakistan is open now. Recruiting first, the newest first:
Sehat Medical Complex · Sites in Pakistan
Ages 40–60
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 40 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 48 across 333 interventional studies indexed under Tendinopathy.
Median enrollment 38 across the 11 interventional studies, 80 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 8 most frequent:
Sehat Medical Complex is the lead sponsor of 25 studies on the registry; 5 are open to participants now.
Sehat Medical Complex has 2 studies filed under Tendinopathy — fewer than ten, so there is no comparison to draw.
1 of the studies in Tendinopathy with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07873528Sehat Medical ComplexAnatomical Evaluation of Supraspinatus Through Ultrasonography and Biomechanical Measurements Following Blood Flow Restriction Therapy and Eccentric Exercise in Patients of Supraspinatus Tendinitis. | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Tendinopathy with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized controlled trial will be conducted to get the expected outcomes. Patients of both gender groups with unilateral shoulder pain will be selected with age range 40-60 years from Sehat medical complex and randomly allocated into four groups (Group A, B, C and D) of two different trials (Trial I and Trial II). The sample size will be 120 patients for both trials. Musculoskeletal ultrasound, goniometry, pain pressure threshold, dynamometer and functional indices will be used to measure the tendon thickness, range of motion, pain, muscle strength and function level. The group A will get BFRT, Group B will get ESWT, group c will get the combination of both and group D will be the Control group (Routine physical therapy). In Trial II the group A will get BFRT, Group B will get Eccentric Training, Group C will get combination of both A \& B and group D will be control group. data will be collected at baseline, 4th week, 8th week and 12 week of interventions. For data analysis SPSS version 25 will be used. Repeated measures ANOVA will be applied to compare the quantitative data within and between the groups. Post-Hoc test Tukey and Bonferroni correction will be used. The level of significance will be set at 5% (P\<0.05).
Musculoskeletal (MSK) disorders affect 1.71 billion people globally. In Pakistan 3.7-20% people are suffering from shoulder pain and while other rotator cuff muscles have been targeted with various therapies singly, neither supraspinatus tendinitis has received its due attention nor has the effect of combination of therapies been explored on it. Additionally, using the technique of MSK ultrasound will give us an objective quantitative basis for the anatomical evaluation. The tendon dimensions and biomechanical measurements of the supraspinatus show marked and differential improvement under the influence of different combinations of physical therapies compared to any single therapy.
Objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
4 Sets of exercise with restriction cuff 30,15,15,15 with cable system pulley
Other: Blood flow Restriction therapy
10 minutes shocks of 2000 J/session
Device: ESWT
Interventional study group Combination therapy
Other: Blood flow Restriction therapy · Device: ESWT
Control group with routine physical therapy
Other: Control
BFRT 4 Sets of exercise with restriction cuff 30,15,15,15 with cable system pulley ESWT 10 minutes shocks of 2000 J/session
Also known as: BFRT, ESWT
10 minutes shocks of 2000 J/session
Also known as: Shock wave therapy
Electric heating pad (Besmed, Taiwan) 10 minutes, TENS (Comfy Stim, Taiwan Model #: EV-806) 10 minutes
Also known as: Routine physical therapy
Shoulder Joint Range of Motion from 0-180 degree
shoulder joint ROM will be measured by Goniometer having 360 degree or inclinometer
Time frame: 12 weeks
MSK Ultrasound for shoulder
tendon thickness in long (mm) and short axis (mm)
Time frame: 12 weeks
Shoulder Functional scale
Quick-DASH (Quick-Disability of arm shoulder and hand) functional scale, it is 11 items scale with response range 0-5 on. 0 is no disability and 100 shows severe disability. The scale have 5 response options much worse, somewhat worse, unchanged, somewhat better, much better
Time frame: 12 weeks
Shoulder Joint PAIN
NPRS 0-10 , 10 is the worse imaginable pain and 0 is no pain
Time frame: 12 WEEKS
Shoulder Muscle Strength
Manual muscle testing and Dynamometer
Time frame: 12 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — the study protocol
Supporting information: Study protocol
Time frame: 12 weeks till the trail is recutting
Access criteria: by email, any researcher
Data sharing details ↗ · uvas.edu.pk
Ran from Feb 2026 to primary completion in Nov 2026, 8 months.
Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 8 months is below that.
Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.
Primary completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 17, 2026.
Completion moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sehat Medical Complex